Shares cratered as Sionna Therapeutics lost 92% of its market value in a single session after its lead cystic fibrosis drug produced results statistically indistinguishable from a sugar pill. The collapse wiped out roughly $2.12 billion in equity value , transforming a $51 stock into a $4 one overnight — and leaving investors to ask whether the remaining science justifies any premium over the company's bank account.
The Drug Did Essentially Nothing
The trial tested whether adding Sionna's experimental pill to Vertex Pharmaceuticals' Trikafta — the dominant cystic fibrosis treatment — would further lower sweat chloride levels, a biomarker that reflects how well the disease protein is working. The result: a -1.0 mmol/L improvement over placebo, with a p-value of 0.7 — meaning the outcome was almost certainly due to chance. The trial was designed to detect at least a 10 mmol/L reduction . It missed by a mile. Sionna will no longer advance the drug as an add-on therapy .
The Stock Now Trades Below the Company's Cash
Sionna's gross cash and securities total $268.3 million, surpassing its implied equity value of roughly $182.9 million . In other words, the market is assigning negative value to Sionna's remaining pipeline. Most recent analyst price targets cluster in the $5–$7 range, largely anchored to the cash balance . The company hinted at potential layoffs, saying it will "take actions to preserve capital."
Wall Street Rushed for the Exits
Stifel slashed its target from $55 to $7 and downgraded to Hold; Wedbush cut from $53 to $5; RBC dropped to $5; Raymond James moved from Strong Buy to Market Perform . These revised targets closely track Sionna's gross cash per share, implying analysts see limited upside beyond the cash pile .
Vertex Wins Without Lifting a Finger
Vertex shares rose ~6% as the trial failure removed a potential competitive threat to its cystic fibrosis franchise . Truist analysts noted the failure "underscores the difficulty of demonstrating incremental benefit on top of Vertex's highly effective CFTR modulators." For Sionna, the remaining hope is an early-stage backup compound that passed safety testing in healthy volunteers — but that study did not produce efficacy results in patients, and Sionna has not yet determined a path forward . Investors now hold, in essence, a claim on a shrinking cash balance and an unproven scientific thesis.